Glaukos, based in Aliso Viejo, California, specializes in innovative therapies for glaucoma and retinal diseases, employing 907 staff since its IPO on June 25, 2015. Their products include micro-invasive devices and dropless treatments to reduce intraocular pressure.
Gilbert H Kliman sold 10,000 shares of GKOS on 20 December at $150.28 per share, worth a total of $1.5M. They now own 32,336 GKOS shares, or a 24% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
